MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in...
$204,542K
Proceeds from issuance of
common stock upon...
$1,231K
Net cash provided by
financing activities
$201,841K
Effect of exchange rate
changes on cash and cash...
$7K
Canceled cashflow
$3,932K
Net increase in
cash, cash...
$69,730K
Canceled cashflow
$132,118K
Payment of third-party
ipo costs
$3,932K
Accounts payable
$6,319K
Stock-based compensation
$3,280K
Loss on
remeasurement of convertible...
$1,377K
Depreciation and
amortization expense
$1,134K
Non-cash operating lease
costs
$684K
Operating lease
liabilities
$184K
Provision for expected
credit losses
$135K
Unrealized foreign
exchange loss (gain)
-$80K
Amortization of debt issuance
costs
$70K
Change in fair value of
warrant liabilities
$33K
Net cash (used in)
provided by investing...
-$120,796K
Net cash used in
operating activities
-$11,322K
Canceled cashflow
$13,296K
Purchases of short-term
investments
$117,045K
Purchases of property and
equipment
$3,642K
Capitalized software
development costs
$109K
Net loss
-$13,199K
Inventory
$5,725K
Accrued expenses and
other liabilities
-$3,206K
Accounts receivable
$967K
Prepaid expenses and
other current assets
$900K
Other noncurrent
assets
$484K
Accretion and
amortization of premiums and...
$137K
Back
Back
Cash Flow
Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. (ALMR)
source: myfinsight.com